Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Lung Cancer

Free Subscription 15.12.2025 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Ind Med 1 Ann Oncol 9 Ann Surg Oncol 1 Ann Thorac Surg 1 Arch Pathol Lab Med 6 BMC Cancer 2 Br J Cancer 2 Cancer 1 Cancer Cell 3 Cancer Lett 3 Cancer Sci 1 Carcinogenesis 3 Chest 3 Clin Lung Cancer 3 Clin Nucl Med 3 Eur J Cancer 3 Eur J Cardiothorac Surg 1 Int J Cancer 2 Int J Oncol 2 J Clin Oncol 1 J Thorac Cardiovasc Surg 7 J Thorac Oncol 1 Lancet Oncol 9 Lung Cancer 2 Nat Genet 1 Oncol Rep 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LI Y, Long Y, Zheng Y, Liang J, et al
   Ternary-Classification Habitat Model for Invasiveness and Grade of Lung Adenocarcinoma Presenting as a Subsolid Nodule on Low-Dose Chest CT: A Multicenter Study.
   AJR Am J Roentgenol. 2025 Aug 20. doi: 10.2214/AJR.25.33352.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. KRISHNAN N, Lee P, Boldt G, Lakkunarajah S, et al
   Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2025 Dec 9. doi: 10.1097/COC.0000000000001265.
   PubMed         Abstract available
   
   

   
   Am J Ind Med

3. RINGEN K, Dement JM, Almashat S, Cloeren M, et al
   Evaluation of Early Lung Cancer Detection in a Population at High Risk due to Occupation.
   Am J Ind Med. 2025 Dec 8. doi: 10.1002/ajim.70041.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. WANG C, Wang W, Liu H, Chen Q, et al
   Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial.
   Ann Oncol. 2025 Dec 2:S0923-7534(25)06287-8. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. FAJARDO V, Garcia-Cabo B, Rami-Porta R, Martinez-Palau M, et al
   Systematic Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Compared with Targeted EBUS-TBNA for Mediastinal Staging of Locally Advanced Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Dec 13. doi: 10.1245/s10434-025-18551.
   PubMed         Abstract available
   
   
6. CHENG JJ, Dai ZY, Wang FQ, Zhang HL, et al
   Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Patients with Stage I NSCLC with Spread through Air Spaces.
   Ann Surg Oncol. 2026;33:453-466.
   PubMed         Abstract available
   
   
7. KONG C, Zheng L, Cao J, Hu X, et al
   Development and Validation of a Pathomics-Based Prognostic Model for Patients with Lung Adenocarcinoma Undergoing First-Line EGFR-TKI Therapy.
   Ann Surg Oncol. 2026;33:501-517.
   PubMed         Abstract available
   
   
8. KHAN AA, Naeem W, Shah SK, Ansari M, et al
   Association Between Postoperative Skeletal Muscle Loss and Disease-Free Survival in Node-Negative NSCLC
   Ann Surg Oncol. 2026;33:530-538.
   PubMed         Abstract available
   
   
9. VAKOUFTSI AC, Constantine A, Dimitrios A, Kostantinos V, et al
   Risk Factors for Recurrence of Non-Small-Cell Lung Cancer After Anatomical Segmentectomy.
   Ann Surg Oncol. 2025 Dec 11. doi: 10.1245/s10434-025-18878.
   PubMed         Abstract available
   
   
10. FAJARDO V, Martinez-Palau M, Sanz-Santos J
    ASO Author Reflections: Systematic Mediastinal Staging Through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients with Lung Cancer.
    Ann Surg Oncol. 2025 Dec 10. doi: 10.1245/s10434-025-18625.
    PubMed        
    
    
11. SHANG F, Huang M, Ji Y, Zhang S, et al
    Harnessing Machine Learning and Multiomics to Construct a Tumor-Specific T Cell Signature for Prognostic Assessment and Precision Medicine in Lung Adenocarcinoma.
    Ann Surg Oncol. 2026;33:769-788.
    PubMed         Abstract available
    
    
12. SCHAFER L, Holzner PA, Menzel M, Stoger GJ, et al
    Iterative Hepatic and Pulmonary Metastasectomy in Stage IV Colorectal Cancer: Impact on Survival and Surgical Outcomes.
    Ann Surg Oncol. 2025 Sep 30. doi: 10.1245/s10434-025-18407.
    PubMed         Abstract available
    
    
13. LADAGE VP, Ramkumar N, Wang Q, O'Malley AJ, et al
    Rurality and Use of Metastasis-Directed Therapies for Medicare Beneficiaries with Metastatic Colon Cancer: A Retrospective Cohort Study.
    Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18412.
    PubMed         Abstract available
    
    

    
    Ann Thorac Surg

14. PAN H, Luo Q
    Exploring Prognostic Models and Molecular Mechanisms in Early-Stage Non-Small Cell Lung Cancer with Tumor Spread Through Air Spaces.
    Ann Thorac Surg. 2025 Dec 3:S0003-4975(25)01184.
    PubMed        
    
    

    
    Arch Pathol Lab Med

15. ELSNER F, Zustin J, Weber F, Rummele P, et al
    Ultrastaging Confirms the Superior Sensitivity of Quantitative Immunocytology for Detection of Lymph Node Spread in Non-Small Cell Lung Cancer Patients.
    Arch Pathol Lab Med. 2025 Dec 12. doi: 10.5858/arpa.2025-0162.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. BERRESSEM S, Moos LT, Roder J, Harzheim L, et al
    Uncovering gaps in personalised lung cancer care in Germany: a white spot analysis.
    BMC Cancer. 2025 Dec 12. doi: 10.1186/s12885-025-15411.
    PubMed         Abstract available
    
    
17. AI J, Li H, Wang M, Zhao L, et al
    Development and validation of a CT-radiomics model for the diagnosis of lung cancer associated with cystic airspaces: a multicenter study.
    BMC Cancer. 2025 Dec 9. doi: 10.1186/s12885-025-15434.
    PubMed         Abstract available
    
    
18. WEI Y, Li R, Liu X, Shi Y, et al
    Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.
    BMC Cancer. 2025 Dec 7. doi: 10.1186/s12885-025-15327.
    PubMed         Abstract available
    
    
19. FAN X, Wang S, Li W, Wang R, et al
    Quantifying interplay effects in lung cancer IMPT: a comprehensive analysis of treatment planning parameter sensitivity.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15416.
    PubMed         Abstract available
    
    
20. FU S, Li L, Ou Z, Lin C, et al
    Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer.
    BMC Cancer. 2025;25:1854.
    PubMed         Abstract available
    
    
21. SHI Y, Lei Y, Liu Y, Zhao W, et al
    Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15259.
    PubMed        
    
    

    
    Br J Cancer

22. GUO Z, Chen J, Zhang S, Xie J, et al
    RNLS hypomethylation as a potential epigenetic marker of lung cancer metastasis: an epigenome-wide association study.
    Br J Cancer. 2025 Dec 10. doi: 10.1038/s41416-025-03283.
    PubMed         Abstract available
    
    
23. ERNHOFER B, Solta A, Sinner J, Megyesfalvi Z, et al
    Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer.
    Br J Cancer. 2025 Dec 13. doi: 10.1038/s41416-025-03276.
    PubMed         Abstract available
    
    

    
    Cancer

24. HUANG Z, Ruan Z, Xu S, Zou N, et al
    Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.
    Cancer. 2025;131:e70126.
    PubMed         Abstract available
    
    
25. BRINZEVICH D, Falvello V, Rehmani SS, Strohbehn GW, et al
    The effect of common medications on the efficacy of immune checkpoint inhibitors.
    Cancer. 2025;131:e70222.
    PubMed         Abstract available
    
    

    
    Cancer Cell

26. SASAKI N, Homme M, Kitajima S
    Mapping the inflammatory origins of lung cancer.
    Cancer Cell. 2025 Dec 11:S1535-6108(25)00498-2. doi: 10.1016/j.ccell.2025.
    PubMed         Abstract available
    
    

    
    Cancer Lett

27. SHEN A, Zheng S, Tang X, Yao Y, et al
    Integrated multi-omics analyses identified the H3K18la-based spatiotemporal characteristics and risk-stratified treatment strategy in lung adenocarcinoma.
    Cancer Lett. 2026;638:218158.
    PubMed         Abstract available
    
    
28. GAO Y, Li LX, Rowland A, Karapetis CS, et al
    Progressive Lesion Type is Predictive of Post-progression Survival in First-line Chemoimmunotherapy for Non-small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 10:218191. doi: 10.1016/j.canlet.2025.218191.
    PubMed        
    
    
29. ZHANG WY, Wang ZQ, Fan XX
    Overcoming EGFR TKI Resistance and Immunosuppression in Non-Small Cell Lung Cancer via EGFR/TLR9/PD-L1 Triple-Targeted Therapy.
    Cancer Lett. 2025 Dec 10:218217. doi: 10.1016/j.canlet.2025.218217.
    PubMed        
    
    

    
    Cancer Sci

30. LI J, Zhao F, Wang Z, Yang S, et al
    KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.
    Cancer Sci. 2025 Dec 9. doi: 10.1111/cas.70286.
    PubMed         Abstract available
    
    
31. TAKAYAMA-ISAGAWA Y, Komura D, Isagawa T, Amano Y, et al
    A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models.
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70270.
    PubMed         Abstract available
    
    
32. YOSHIOKA H, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70242.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

33. ZHANG S, Cai J, Feng Y, Yang M, et al
    Tumor-associated astrocytes inhibit tumor cell apoptosis through TNF-alpha-TNF receptor 2-NF-kappaB pathway in lung cancer brain metastasis.
    Carcinogenesis. 2025 Dec 13:bgaf090. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Chest

34. KWAK HS, Lee J, Choi CM, Jung YJ, et al
    Impact of chronic lung disease, socioeconomic status, and family history on lung cancer risk in never-smokers: a matched case-control study.
    Chest. 2025 Dec 10:S0012-3692(25)05840-4. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
35. BELTRAMI M, Papi M, Olivotto I, Santi R, et al
    An Unexpected Cause of Asymmetric Left Ventricular Hypertrophy.
    Chest. 2025;168:e171-e177.
    PubMed         Abstract available
    
    
36. EZENWANKWO E, Yell N, Eberth JM
    Lung Cancer Screening in the United States, 2024: A National Health Interview Survey Analysis.
    Chest. 2025 Dec 8:S0012-3692(25)05818-0. doi: 10.1016/j.chest.2025.
    PubMed        
    
    

    
    Clin Lung Cancer

37. DESAI PA, Borghaei H, Edelman MJ
    Neoadjuvant Chemo-Immunotherapy for Surgically Resectable Non-Small Cell Lung Cancer: Balancing Promise and Pitfalls.
    Clin Lung Cancer. 2025;27:55-58.
    PubMed         Abstract available
    
    
38. VELO AE, Mudd J, Slatore CG, Flores R, et al
    Factors Associated With Provider Decision-Making of Early-Stage Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy or Sublobar Resection.
    Clin Lung Cancer. 2025;27:59-69.
    PubMed         Abstract available
    
    
39. GUAY CA, Suhani A, Perreault L, Mai V, et al
    Response to the letter to the Editor on "The Changing Landscape of Lung Cancer Resection Outcomes Over the Past Two Decades".
    Clin Lung Cancer. 2025;27:70-71.
    PubMed        
    
    

    
    Clin Nucl Med

40. ZHENG L, Zhou Z, Zhang K, Xie P, et al
    68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.
    Clin Nucl Med. 2026;51:65-67.
    PubMed         Abstract available
    
    
41. FAN M, Guo X, Liu G, Tian C, et al
    Exploratory Analysis of [68Ga]Ga-FAP-2286 PET/CT Quantitative Parameters for Predicting Response to [177Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer.
    Clin Nucl Med. 2025 Nov 18. doi: 10.1097/RLU.0000000000006210.
    PubMed         Abstract available
    
    
42. YOO SJ, Lee H, Myung JK, Choi YY, et al
    Rapid Spontaneous Tumor Regression Mimicking Pseudoprogression in Pembrolizumab-treated Non-small Cell Lung Cancer.
    Clin Nucl Med. 2025 Nov 19. doi: 10.1097/RLU.0000000000006228.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

43. CUPPENS K, Wiesweg M, Baas P, Maes B, et al
    Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).
    Eur J Cancer. 2025;233:116165.
    PubMed         Abstract available
    
    
44. FATTORE D, Bernardi FF, Esposito G, Megna M, et al
    Successful treatment of durvalumab-induced psoriasis in an HBV-positive lung cancer patient with Risankizumab: A novel case report.
    Eur J Cancer. 2025;232:116156.
    PubMed        
    
    
45. ADDEO A, Dietrich D, Mach N, Mark MT, et al
    Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19).
    Eur J Cancer. 2025;232:116138.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

46. MIMAE T, Miyata Y, Tsubokawa N, Kanno C, et al
    Loco-regional Recurrence After Segmentectomy for Peripheral and Radiologically Solid-dominant Tumours.
    Eur J Cardiothorac Surg. 2025;67:ezaf416.
    PubMed         Abstract available
    
    
47. SHINDO Y, Fumimoto S, Hanaoka N, Toyohara K, et al
    Which Risk Score Best Predicts Prolonged Air Leak After Lobectomy? A Comparative Evaluation Study.
    Eur J Cardiothorac Surg. 2025;67:ezaf429.
    PubMed         Abstract available
    
    
48. GIVIGLIANO F, Ferrazzo T, Sassorossi C, Lococo F, et al
    The role of lymphadenectomy in different non-small-cell lung cancer stages.
    Eur J Cardiothorac Surg. 2025 Dec 9:ezaf440. doi: 10.1093.
    PubMed        
    
    

    
    Int J Cancer

49. SU J, Hua J, Fan X, Wan X, et al
    Associations of diabetes status, duration, and onset age with the risk of lung cancer: Results from the China Kadoorie Biobank study.
    Int J Cancer. 2025 Dec 12. doi: 10.1002/ijc.70294.
    PubMed         Abstract available
    
    

    
    Int J Oncol

50. GAO J, Mcconnell MJ, Yu B, Li J, et al
    [Expression of Concern] MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.
    Int J Oncol. 2026;68:16.
    PubMed         Abstract available
    
    
51. PANG X, Liu H, Long Y, Wang H, et al
    mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review).
    Int J Oncol. 2026;68:21.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

52. HE J, Zheng B, Wang Z
    Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity.
    J Clin Oncol. 2025 Dec 10:JCO2501540. doi: 10.1200/JCO-25-01540.
    PubMed        
    
    
53. FELIP E, Wakelee HA, Fu C, Deng Y, et al
    Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
    J Clin Oncol. 2025 Dec 10:JCO2502102. doi: 10.1200/JCO-25-02102.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

54. TSUI ST, Tan KS, Zheng J, Gray KD, et al
    Surgical Outcomes Using Three-Dimensional Image Simulation for Segmentectomy Planning in Patients with Stage IA1-2 Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2025 Dec 5:S0022-5223(25)01042.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

55. BOLAND JM, Lo YC, Mansfield AS
    Immune Checkpoint Inhibitor Monotherapy for Patients With Pulmonary Sarcomatoid Carcinoma-The Optimal Therapeutic Strategy for This Rare Lung Cancer Subtype?
    J Thorac Oncol. 2025;20:1735-1736.
    PubMed        
    
    
56. GOODLEY P, Balata H, Alonso A, Sharman A, et al
    Population impact of risk-based lung cancer screening on late-stage incidence in Greater Manchester.
    J Thorac Oncol. 2025 Dec 2:S1556-0864(25)02908.
    PubMed         Abstract available
    
    
57. YEH YC, Chiang CH, Hsu PK, Wang LC, et al
    Tumor Cell Invasion of the External Elastic Lamina Designates Visceral Pleural Invasion and Predicts Poorer Patient Outcomes in Pulmonary Nonmucinous Invasive Adenocarcinoma.
    J Thorac Oncol. 2025;20:1791-1800.
    PubMed         Abstract available
    
    
58. HONG L, Di Federico A, Liu B, Cooper AJ, et al
    Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
    J Thorac Oncol. 2025;20:1763-1777.
    PubMed         Abstract available
    
    
59. PETERS S, Schulz C, Reck M, Prabhash K, et al
    Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
    J Thorac Oncol. 2025;20:1843-1850.
    PubMed         Abstract available
    
    
60. FADUL MJS, Mendoza MJL, Sacdalan DBL, Samala KG, et al
    Lung Cancer in the Philippines.
    J Thorac Oncol. 2025;20:1747-1752.
    PubMed        
    
    
61. LIU Y, Li Y, Byun J, Shaw VR, et al
    High penetrance rare variants underlying familial lung cancer risk: Insights from genetic epidemiology of lung cancer consortium.
    J Thorac Oncol. 2025 Dec 11:S1556-0864(25)02942.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

62. WU YL, Yao Y, Yang JJ, Wu L, et al
    Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
    Lancet Oncol. 2025 Dec 6:S1470-2045(25)00594.
    PubMed         Abstract available
    
    

    
    Lung Cancer

63. WANG X, Shi W, Xiao Y, Wang H, et al
    The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significance.
    Lung Cancer. 2025;210:108817.
    PubMed         Abstract available
    
    
64. LUO YH, Yang CC, Wu SC, Su HW, et al
    A novel agent, p-toluenesulfonamide, in the management of malignant pleural effusions.
    Lung Cancer. 2025;210:108814.
    PubMed         Abstract available
    
    
65. HEIJBOER FWJ, Derks JL, van Nederveen FH, Hillen LM, et al
    Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study.
    Lung Cancer. 2025;210:108830.
    PubMed         Abstract available
    
    
66. ISHIDA M, Yamada T, Tsunashima R, Morita M, et al
    Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database.
    Lung Cancer. 2025;210:108843.
    PubMed         Abstract available
    
    
67. SHAROVA E, Del Bianco P, Urso L, Silic-Benussi M, et al
    Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.
    Lung Cancer. 2025;210:108852.
    PubMed         Abstract available
    
    
68. WU L, Li J, Xu CR, Biswas B, et al
    Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.
    Lung Cancer. 2025;211:108856.
    PubMed         Abstract available
    
    
69. DODD RH, Weber M, McFadden K, Rankin NM, et al
    Informed choice for lung cancer screening: A randomised trial of three decision support tools.
    Lung Cancer. 2025;211:108874.
    PubMed         Abstract available
    
    
70. CHO BC, Charoentum C, Kim DW, Yang CT, et al
    MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naive metastatic non-small-cell lung cancer.
    Lung Cancer. 2025;211:108834.
    PubMed         Abstract available
    
    
71. PETERS BJM, Bohringer S, van Geffen E
    Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer".
    Lung Cancer. 2025;211:108872.
    PubMed        
    
    

    
    Nat Genet

72. PANJA S, Mantri P, Johnson KE, Andrade-Martinez JS, et al
    Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas.
    Nat Genet. 2025;57:3066-3074.
    PubMed         Abstract available
    
    
73. LIU M, Jin S, Agabiti SS, Jensen TB, et al
    Tracing the evolution of single-cell 3D genomes in Kras-driven cancers.
    Nat Genet. 2025;57:3075-3087.
    PubMed         Abstract available
    
    

    
    Oncol Rep

74. JIN L, Wei L, Hua J, Zhang R, et al
    Inhibition of primary ciliogenesis enhances efficacy of EGFR?TKIs against non?small cell lung cancer cells.
    Oncol Rep. 2026;55:30.
    PubMed         Abstract available
    
    

    
    PLoS One

75. DHOUIB W, Maatouk A, Bennasrallah C, Kacem M, et al
    Incidence and survival of Lung Cancer: A retrospective population-based cohort (Monastir, Tunisia: 2002-2022).
    PLoS One. 2025;20:e0338140.
    PubMed         Abstract available
    
    
76. HOBSON LM, Martin RM, Smith-Byrne K, Davey Smith G, et al
    A protocol for using human genetic data to identify circulating protein level changes that are the causal consequence of cancer processes.
    PLoS One. 2025;20:e0312970.
    PubMed         Abstract available
    
    
77. BAE BK, Kim SJ, Kim JC
    Influence of inter-fractional respiratory motion changes on dose delivery accuracy in dynamic conformal arc lung stereotactic body radiotherapy: A phantom study.
    PLoS One. 2025;20:e0336475.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

78. WANG X, Sun J, Lan B, Wang C, et al
    Asparagine endopeptidase prompts breast cancer-related pericardial calcification by regulating IGF2 and integrin alphavbeta5.
    Proc Natl Acad Sci U S A. 2025;122:e2512936122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.